Tender detail
Conclusion of a non-exclusive pharmaceutical discount agreement for Faricimab (ATC S01LA09) for the period 1 October 2026 to 30 September 2028
Summary
The tender concerns the conclusion of non-exclusive pharmaceutical discount agreements for medicines containing the active substance Faricimab (ATC S01LA09). DAK-Gesundheit intends to conclude agreements with as many interested pharmaceutical companies as possible for medicines to be specified by the bidder in Annex 2 to the agreement. The agreements are intended to run from 1 October 2026 to 30 September 2028 and will end automatically if an exclusive agreement for the active substance enters into force.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.